FibroBiologics, Inc. Common Stock (FBLG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, FibroBiologics, Inc. Common Stock (FBLG) has a cash flow conversion efficiency ratio of -31.776x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.97 Million) by net assets ($125.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
FibroBiologics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how FibroBiologics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does FibroBiologics, Inc. Common Stock carry for a breakdown of total debt and financial obligations.
FibroBiologics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of FibroBiologics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eastparc Hotel Tbk PT
JK:EAST
|
0.013x |
|
PPK Group Ltd
AU:PPK
|
-0.034x |
|
Z-Com Inc
TWO:8176
|
-0.001x |
|
Glunz & Jensen
CO:GJ
|
0.047x |
|
Moleculin Biotech Inc
NASDAQ:MBRX
|
0.268x |
|
WIIK Public Company Limited
BK:WIIK
|
0.009x |
|
TPC Plus Bhd
KLSE:7176
|
0.117x |
|
Indara Insurance Public Company Limited
BK:INSURE
|
0.071x |
Annual Cash Flow Conversion Efficiency for FibroBiologics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of FibroBiologics, Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see FBLG stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $2.73 Million | $-11.90 Million | -4.351x | +14.82% |
| 2024-06-30 | $1.25 Million | $-6.40 Million | -5.109x | -602.06% |
| 2023-06-30 | $-4.00 Million | $-4.07 Million | 1.018x | -6.91% |
| 2022-06-30 | $-1.29 Million | $-1.41 Million | 1.093x | -- |
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications. The company was founded in 2021 and is based in Houston, Texas.